Cidara Therapeutics (FRA:20D0) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cidara Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was €-28.09 Mil. Cidara Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Cidara Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Cidara Therapeutics's current FCF Yield % is -72.03%.

The historical rank and industry rank for Cidara Therapeutics's FCF Margin % or its related term are showing as below:

FRA:20D0' s FCF Margin % Range Over the Past 10 Years
Min: -13855.84 Med: -117.55 Max: -44.36
Current: -2030.41

During the past 12 years, the highest FCF Margin % of Cidara Therapeutics was -44.36%. The lowest was -13855.84%. And the median was -117.55%.

FRA:20D0's FCF Margin % is ranked worse than
83.5% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs FRA:20D0: -2030.41

Cidara Therapeutics FCF Margin % Historical Data

The historical data trend for Cidara Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics FCF Margin % Chart

Cidara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-452.45

-50.98

-44.36

-98.51

-13,851.56

Cidara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-468.10	-78.77	-34,310.32	-	-

Competitive Comparison of Cidara Therapeutics's FCF Margin %

For the Biotechnology subindustry, Cidara Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cidara Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Cidara Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cidara Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-168.712	/	1.218
	=	-13,851.56 %

Cidara Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-28.09	/	0
	=	%

Cidara Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CDTX:USA 20D0:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines